Perrigo Growth Trajectory Traverses Manufacturing, Licensing Headwinds
This article was originally published in The Tan Sheet
Executive Summary
Perrigo omitted from its fiscal 2015 guidance revenues from generic guaifenesin expectorants because raw material sourcing has not met manufacturing specifications and continues to hold up production. The firm’s plans for launching store brand OTC nasal corticosteroids also are in limbo.